Breaking Down SG&A Expenses: Amgen Inc. vs Opthea Limited

A Tale of Two Companies: Amgen Inc. vs. Opthea Limited

In the ever-evolving pharmaceutical landscape, understanding the financial dynamics of industry giants like Amgen Inc. and emerging players such as Opthea Limited is crucial. Over the past decade, Amgen's Selling, General, and Administrative (SG&A) expenses have shown a steady increase, peaking at approximately $6.2 billion in 2023, reflecting a 31% rise since 2014. This growth underscores Amgen's expansive operational strategies and market penetration.

Conversely, Opthea Limited, a smaller entity, has experienced a dramatic surge in SG&A expenses, skyrocketing from a modest $2.7 million in 2014 to an impressive $41.9 million in 2023. This represents a staggering 1,450% increase, highlighting Opthea's aggressive investment in growth and development. The data for 2024 is incomplete, indicating potential shifts in financial strategies. This comparative analysis offers a fascinating glimpse into the strategic priorities of these two distinct players in the pharmaceutical sector.